Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.
Ipilimumab Approval Highlights Immunotherapy Renaissance
March 25, 2011 By Leave a Comment
On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 3 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Cancer Vaccine Therapies: Failures and Future Opportunities
April 7, 2010 By 3 Comments
(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]
Follow MD Becker Partners